VRPX Insider Trading (Virpax Pharmaceuticals)
Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): $716.00
Insider Selling (Last 12 Months): $0.00
Virpax Pharmaceuticals Insider Trading History Chart
Virpax Pharmaceuticals Share Price & Price History
As of 06/22/2021 01:25 PM ET
Is this Seattle Penny Pot Stock a Potential Blockbuster?
A small, rapidly expanding Seattle cannabis company is gaining attention from investors. Founded by two cannabis veterans, the company has increased sales 8-fold and is looking to double sales again in the next two years. Now selling for less than $1 per share, this is an opportunity to acquire thousands of shares – a potential windfall.
Get Free Report on #1 Cannabis Pick for 2021
Virpax Pharmaceuticals Insider Trading History
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|2/17/2021||Thani Jambulingam||Director||Buy||100||$7.16||$716.00||100|| |
SEC Filings (Institutional Ownership Changes) for Virpax Pharmaceuticals (NASDAQ:VRPX)
5.55% of Virpax Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.
Virpax Pharmaceuticals Institutional Trading History
Data available starting January 2016
|Reporting Date||Hedge Fund||Shares Held||Market Value||% of Portfolio||Quarterly Change in Shares||Ownership in Company||Details|
|5/14/2021||HN Saltoro Capital LP||27,000||$0.13M||0.0%||N/A||0.546%|
Virpax Pharmaceuticals, Inc., a preclinical stage biopharmaceutical company, develops and manufactures non-opioid and non-addictive pharmaceutical products using drug delivery systems for pain management. The company offers products, such as Epoladerm, a diclofenac metered-dose spray film for acute musculoskeletal pain; Probudur (LBL100), long-acting bupivacaine liposomal gel for postoperative pain management; OSF200 for chronic osteoarthritis of the knee; and NES100 (Envelta), an exogenous enkephalin intranasal spray for acute and chronic pain. It also develops PES200 for the management of post-traumatic stress disorder; and MMS019 high-density molecular masking spray to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2 (Covid-19). Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.
50 Day Range
52 Week Range
Who are the company insiders with the largest holdings of Virpax Pharmaceuticals?
Virpax Pharmaceuticals' top insider investors include:
- Thani Jambulingam (Director)
Who are the major institutional investors of Virpax Pharmaceuticals?
Virpax Pharmaceuticals' top institutional shareholders include:
- HN Saltoro Capital LP — 0.55%
Which institutional investors are buying Virpax Pharmaceuticals stock?
Within the previous quarter, VRPX stock was acquired by institutional investors including:
- HN Saltoro Capital LP